A collaboration among 157 newborn screening programs in 47 countries has lead to the creation of a database of 705,333 discrete analyte concentrations from 11,462 cases affected with 57 metabolic disorders, and from 631 heterozygotes for 12 conditions. This evidence was first applied to establish disease ranges for amino acids and acylcarnitines, and clinically validate 114 cutoff target ranges. Objective: To improve quality and performance with an evidence-based approach, multivariate pattern recognition software has been developed to aid in the interpretation of complex analyte profiles. The software generates tools that convert multiple clinically significant results into a single numerical score based on overlap between normal and disease ranges, penetration within the disease range, differences between specific conditions, and weighted correction factors. Design: Eighty-five on-line tools target either a single condition or the differential diagnosis between two or more conditions. Scores are expressed as a numerical value and as the percentile rank among all cases with the condition chosen as primary target, and are compared to interpretation guidelines. Tools are updated automatically after any new data submission (2009- 2011: 5.2 new cases added per day on average). Main outcome measures: Retrospective evaluation of past cases suggest that these tools could have avoided at least half of 277 false positive outcomes caused by carrier status for fatty acid oxidation disorders, and could have prevented 88% of false negative events caused by cutoff 7 values set inappropriately. In Minnesota, their prospective application has been a major contributing factor to the sustained achievement of a false positive rate below 0.1% and a positive predictive value above 60%. Conclusions: Application of this computational approach to raw data could make cutoff values for single analytes effectively obsolete. This paradigm is not limited to newborn screening and is applicable to the interpretation of diverse multi-analyte profiles utilized in laboratory medicine. Abstract word

Enhanced interpretation of newborn screening results without analyte cutoff values / Gregg Marquardt, 1; Robert, Currier; Phd, 2; David M. S., McHugh 1; Dimitar, Gavrilov; Md, ; Phd, 1; Mark J., Magera 1; Dietrich, Matern; Md, 1; Devin, Oglesbee; Phd, 1; Kimiyo, Raymond; Md, 1; Piero, Rinaldo; Md, ; Phd, 1; Emily H., Smith; Phd, 1; Silvia, Tortorelli; Md, ; Phd, 1; Coleman T., Turgeon 1; Fred, Lorey; Phd, 2; Bridget, Wilcken; Md, 3; Veronica, Wiley; Phd, 3; Lawrence C., Greed; Bsc, 4; Barry, Lewis; Md, 4; François, Boemer; PharmD PhD, 5; Roland, Schoos; Phd, 5; Sandrine, Marie; Phd, 6; Marie Françoise, Vincent; Md, ; Phd, 6; Yuri Cleverthon, Sica; Msc, 7; Mouseline Torquado Domingos, 7; Khalid Al, Thihli; Md, 8; Graham, Sinclair; Phd, 8; Osama Y., Al Dirbashi; Phd, 9; Pranesh, Chakraborty; Md, 9; Mark Dymerski, 10; Cory Porter, 10; Adrienne, Manning; 11, ; Margretta R., Seashore; Md, 12; Jonessy, Quesada; Md, 13; Alejandra Reuben, 13; Petr, Chrastina; Msc, 14; Petr, Hornik; Phd, 14; Iman Atef, Mandour; Md, 15; Sahar Abdel Atty, Sharaf; Md, 15; Olaf, Bodamer; Md, ; Phd, 16; Bonifacio, Dy; Md, 17; Jasmin Torres, 17; Roberto, Zori; Md, 18; David, Cheillan; Phd, 19; Christine Vianey, Saban; Phd, 19; David Ludvigson, 20; Adrya Stembridge, 21; Jim, Bonham; Phd, 22; Melanie, Downing; Msc, 22; Yannis, Dotsikas; Phd, 23; Yannis L., Loukas; Phd, 23; Vagelis, Papakonstantinou; Phd, 24; Georgios S. A., Zacharioudakis; Phd, 24; Ákos, Baráth; Phd, 25; Eszter, Karg; Md, ; Phd, 25; Leifur, Franzson; Phd, 26; Jon J., Jonsson; Md, ; Phd, 26; Nancy N., Breen 27; Barbara G., Lesko 27; Stanton L., Berberich; Phd, 28; Kimberley, Turner; Rn, 29; Ruoppolo, Margherita; Md, 30; Emanuela Scolamiero, 30; Italo, Antonozzi; Md, 31; Claudia, Carducci; Ms, 31; Ubaldo Caruso, 32; Michela Cassanello, 32; Giancarlo la, Marca; Pharm Sc, 33; Elisabetta, Pasquini; Md, 34; Iole Maria Di, Gangi; Phd, 35; Giuseppe, Giordano; Phd, 35; Marta, Camilot; Phd, 36; Francesca Teofoli, 36; Shawn M., Manos; Bs, 37; Colleen K., Peterson; Bs, 37; Stephanie K., Mayfield Gibson; Md, 38; Darrin W., Sevier 38; Soo Youn, Lee; Md, ; Phd, 39; Hyung2 Doo, Park; Md, ; Phd, 39; Issam, Khneisser; Ms, 40; Phaidra Browning, 41; Fizza Gulamali, Majid; Phd, 42; Michael S., Watson; Phd, 43; Roger B., Eaton; Phd, 44; Inderneel, Sahai; Md, 44; Consuelo Ruiz, 45; Rosario Torres, 45; Mary A., Seeterlin; Phd, 46; Eleanor L., Stanley 46; Amy Hietala, 47; Mark McCann, 47; Carlene Campbell, 48; Patrick V., Hopkins 48; Monique G., de Sain Van der Velden; Phd, 49; Bert Elvers, 50; Mark A., Morrissey; Phd, 51; Sherlykutty Sunny, 51; Detlef, Knoll; Msc, 52; Dianne, Webster; Phd, 52; Dianne M., Frazier; Phd, 53; Julie D., Mcclure; Mph, 53; David E., Sesser 54; Sharon A., Willis 54; Hugo, Rocha; Msc, 55; Laura, Vilarinho; Phd, 55; Catharine, John; Phd, 56; James, Lim; Phd, 56; S., Graham Caldwell 57; Kathy, Tomashitis; Mns, 57; Daisy E., Castiñeiras Ramos 58; Jose Angel Cocho de, Juan; Phd, 58; Inmaculada Rueda, Fernández; Md, 59; Raquel Yahyaoui, Macías; Md, 59; José María Egea Mellado, 60; Inmaculada González, Gallego; Phd, 60; Carmen Delgado, Pecellin; Phd, 61; Maria Sierra García Valdecasas, Bermejo; Phd, 61; Yin Hsiu, Chien; Md, ; Phd, 62; Wuh Liang, Hwu; Md, ; Phd, 62; Thomas, Childs; Mt, 63; Christine D., McKeever 63; Tijen, Tanyalcin; Md, ; Phd, 64; Mahera, Abdulrahman; Md, ; Phd, 65; Cecilia, Queijo; Phd, 66; Aída, Lemes; Md, 66; Tim Davis, 67; William Hoffman, 67; Mei, Baker; Md, 68; Gary, L. Hoffman 6. 8.. - In: GENETICS IN MEDICINE. - ISSN 1098-3600. - 10:(2012), pp. 20-30. [10.1038/gim.2012.2.]

Enhanced interpretation of newborn screening results without analyte cutoff values

RUOPPOLO, MARGHERITA;
2012

Abstract

A collaboration among 157 newborn screening programs in 47 countries has lead to the creation of a database of 705,333 discrete analyte concentrations from 11,462 cases affected with 57 metabolic disorders, and from 631 heterozygotes for 12 conditions. This evidence was first applied to establish disease ranges for amino acids and acylcarnitines, and clinically validate 114 cutoff target ranges. Objective: To improve quality and performance with an evidence-based approach, multivariate pattern recognition software has been developed to aid in the interpretation of complex analyte profiles. The software generates tools that convert multiple clinically significant results into a single numerical score based on overlap between normal and disease ranges, penetration within the disease range, differences between specific conditions, and weighted correction factors. Design: Eighty-five on-line tools target either a single condition or the differential diagnosis between two or more conditions. Scores are expressed as a numerical value and as the percentile rank among all cases with the condition chosen as primary target, and are compared to interpretation guidelines. Tools are updated automatically after any new data submission (2009- 2011: 5.2 new cases added per day on average). Main outcome measures: Retrospective evaluation of past cases suggest that these tools could have avoided at least half of 277 false positive outcomes caused by carrier status for fatty acid oxidation disorders, and could have prevented 88% of false negative events caused by cutoff 7 values set inappropriately. In Minnesota, their prospective application has been a major contributing factor to the sustained achievement of a false positive rate below 0.1% and a positive predictive value above 60%. Conclusions: Application of this computational approach to raw data could make cutoff values for single analytes effectively obsolete. This paradigm is not limited to newborn screening and is applicable to the interpretation of diverse multi-analyte profiles utilized in laboratory medicine. Abstract word
2012
Enhanced interpretation of newborn screening results without analyte cutoff values / Gregg Marquardt, 1; Robert, Currier; Phd, 2; David M. S., McHugh 1; Dimitar, Gavrilov; Md, ; Phd, 1; Mark J., Magera 1; Dietrich, Matern; Md, 1; Devin, Oglesbee; Phd, 1; Kimiyo, Raymond; Md, 1; Piero, Rinaldo; Md, ; Phd, 1; Emily H., Smith; Phd, 1; Silvia, Tortorelli; Md, ; Phd, 1; Coleman T., Turgeon 1; Fred, Lorey; Phd, 2; Bridget, Wilcken; Md, 3; Veronica, Wiley; Phd, 3; Lawrence C., Greed; Bsc, 4; Barry, Lewis; Md, 4; François, Boemer; PharmD PhD, 5; Roland, Schoos; Phd, 5; Sandrine, Marie; Phd, 6; Marie Françoise, Vincent; Md, ; Phd, 6; Yuri Cleverthon, Sica; Msc, 7; Mouseline Torquado Domingos, 7; Khalid Al, Thihli; Md, 8; Graham, Sinclair; Phd, 8; Osama Y., Al Dirbashi; Phd, 9; Pranesh, Chakraborty; Md, 9; Mark Dymerski, 10; Cory Porter, 10; Adrienne, Manning; 11, ; Margretta R., Seashore; Md, 12; Jonessy, Quesada; Md, 13; Alejandra Reuben, 13; Petr, Chrastina; Msc, 14; Petr, Hornik; Phd, 14; Iman Atef, Mandour; Md, 15; Sahar Abdel Atty, Sharaf; Md, 15; Olaf, Bodamer; Md, ; Phd, 16; Bonifacio, Dy; Md, 17; Jasmin Torres, 17; Roberto, Zori; Md, 18; David, Cheillan; Phd, 19; Christine Vianey, Saban; Phd, 19; David Ludvigson, 20; Adrya Stembridge, 21; Jim, Bonham; Phd, 22; Melanie, Downing; Msc, 22; Yannis, Dotsikas; Phd, 23; Yannis L., Loukas; Phd, 23; Vagelis, Papakonstantinou; Phd, 24; Georgios S. A., Zacharioudakis; Phd, 24; Ákos, Baráth; Phd, 25; Eszter, Karg; Md, ; Phd, 25; Leifur, Franzson; Phd, 26; Jon J., Jonsson; Md, ; Phd, 26; Nancy N., Breen 27; Barbara G., Lesko 27; Stanton L., Berberich; Phd, 28; Kimberley, Turner; Rn, 29; Ruoppolo, Margherita; Md, 30; Emanuela Scolamiero, 30; Italo, Antonozzi; Md, 31; Claudia, Carducci; Ms, 31; Ubaldo Caruso, 32; Michela Cassanello, 32; Giancarlo la, Marca; Pharm Sc, 33; Elisabetta, Pasquini; Md, 34; Iole Maria Di, Gangi; Phd, 35; Giuseppe, Giordano; Phd, 35; Marta, Camilot; Phd, 36; Francesca Teofoli, 36; Shawn M., Manos; Bs, 37; Colleen K., Peterson; Bs, 37; Stephanie K., Mayfield Gibson; Md, 38; Darrin W., Sevier 38; Soo Youn, Lee; Md, ; Phd, 39; Hyung2 Doo, Park; Md, ; Phd, 39; Issam, Khneisser; Ms, 40; Phaidra Browning, 41; Fizza Gulamali, Majid; Phd, 42; Michael S., Watson; Phd, 43; Roger B., Eaton; Phd, 44; Inderneel, Sahai; Md, 44; Consuelo Ruiz, 45; Rosario Torres, 45; Mary A., Seeterlin; Phd, 46; Eleanor L., Stanley 46; Amy Hietala, 47; Mark McCann, 47; Carlene Campbell, 48; Patrick V., Hopkins 48; Monique G., de Sain Van der Velden; Phd, 49; Bert Elvers, 50; Mark A., Morrissey; Phd, 51; Sherlykutty Sunny, 51; Detlef, Knoll; Msc, 52; Dianne, Webster; Phd, 52; Dianne M., Frazier; Phd, 53; Julie D., Mcclure; Mph, 53; David E., Sesser 54; Sharon A., Willis 54; Hugo, Rocha; Msc, 55; Laura, Vilarinho; Phd, 55; Catharine, John; Phd, 56; James, Lim; Phd, 56; S., Graham Caldwell 57; Kathy, Tomashitis; Mns, 57; Daisy E., Castiñeiras Ramos 58; Jose Angel Cocho de, Juan; Phd, 58; Inmaculada Rueda, Fernández; Md, 59; Raquel Yahyaoui, Macías; Md, 59; José María Egea Mellado, 60; Inmaculada González, Gallego; Phd, 60; Carmen Delgado, Pecellin; Phd, 61; Maria Sierra García Valdecasas, Bermejo; Phd, 61; Yin Hsiu, Chien; Md, ; Phd, 62; Wuh Liang, Hwu; Md, ; Phd, 62; Thomas, Childs; Mt, 63; Christine D., McKeever 63; Tijen, Tanyalcin; Md, ; Phd, 64; Mahera, Abdulrahman; Md, ; Phd, 65; Cecilia, Queijo; Phd, 66; Aída, Lemes; Md, 66; Tim Davis, 67; William Hoffman, 67; Mei, Baker; Md, 68; Gary, L. Hoffman 6. 8.. - In: GENETICS IN MEDICINE. - ISSN 1098-3600. - 10:(2012), pp. 20-30. [10.1038/gim.2012.2.]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/464388
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 99
social impact